Skip to main content

Table 4 Univariate analysis of factors associated with LTFU among HIV-infected adults on antiretroviral therapy

From: Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya

 

Univariable Results (n = 23890)

6 months

12 months

24 months

36 months

OR (95% CI)

P value

OR (95% CI)

P value

OR (95% CI)

P value

OR (95% CI)

P value

Gender

 Male

1.25 (1.15–1.37)

< 0.001

1.18 (1.09–1.27)

< 0.001

1.13 (1.06–1.21)

< 0.001

1.12 (1.06–1.19)

< 0.001

 Female

Ref

 

Ref

 

Ref

 

Ref

 

Age groups

 20–35

1.18 (1.08–1.29)

< 0.001

1.31 (1.21–1.41)

< 0.001

1.42 (1.33–1.51)

< 0.001

1.43 (1.34–1.51)

< 0.001

 36–50

Ref

 

Ref

 

Ref

 

Ref

 

 51+

1.00 (0.86–1.16)

0.967

0.97 (0.85–1.10)

0.607

0.95 (0.85–1.07)

0.419

0.97 (0.87–1.08)

0.555

Marital Status

 Single

1.38 (1.22–1.55)

< 0.001

1.34 (1.21–1.48)

< 0.001

1.27 (1.16–1.39)

< 0.001

1.34 (1.24–1.45)

< 0.001

 Divorced

1.44 (1.29–1.62)

< 0.001

1.41 (1.28–1.56)

< 0.001

1.4 (1.28–1.52)

< 0.001

1.33 (1.23–1.44)

< 0.001

 Married

Ref

 

Ref

 

Ref

 

Ref

 

 Widowed

0.99 (0.85–1.14)

0.833

0.94 (0.83–1.06)

0.280

0.94 (0.85–1.04)

0.243

0.94 (0.85–1.04)

0.214

BMI

 < 18.5

1.65 (1.41–1.94)

< 0.001

1.48 (1.31–1.67)

< 0.001

1.33 (1.20–1.47)

< 0.001

1.23 (1.13–1.34)

< 0.001

 18.5–24.9

Ref

 

Ref

 

Ref

 

Ref

 

 25–29.9

0.54 (0.41–0.72

< 0.001

0.58 (0.46–0.73)

< 0.001

0.63 (0.53–0.76)

< 0.001

0.66 (0.58–0.76)

< 0.001

 30+

0.49 (0.36–0.66)

< 0.001

0.50 (0.41–0.69)

< 0.001

0.61 (0.51–0.73)

< 0.001

0.67 (0.57–0.8)

< 0.001

CD4

 0–250

1.70 (1.47–1.96)

< 0.001

1.6 (1.42–1.80)

< 0.001

1.34 (1.22–1.47)

< 0.001

1.30 (1.20–1.41)

< 0.001

 251–500

Ref

 

Ref

 

Ref

 

Ref

 

 Above 500

1.91 (1.09–3.32)

0.023

1.55 (0.94–2.55)

0.086

1.70 (1.13–2.56)

0.011

1.53 (1.05–2.25)

0.028

Regimen Started

 D4T-based

Ref

 

Ref

 

Ref

 

Ref

 

 ABC-based

2.09 (1.62–2.68)

< 0.001

2.17 (1.74–2.73)

< 0.001

2.15 (1.74–2.66)

< 0.001

2.01 (1.63–2.48)

< 0.001

 AZT-based

0.66 (0.59–0.75)

< 0.001

0.69 (0.62–0.76)

< 0.001

0.73 (0.67–0.80)

< 0.001

0.81 (0.75–0.88)

< 0.001

 TDF-based

0.57 (0.51–0.64)

< 0.001

0.62 (0.56–0.68)

< 0.001

0.69 (0.64–0.75)

< 0.001

0.81 (0.75–0.87)

< 0.001

Baseline WHO Stage

 Stage I

Ref

 

Ref

 

Ref

 

Ref

 

 Stage II

1.16 (0.99–1.37)

0.0707

1.19 (1.04–1.36)

0.01

1.13 (1.01–1.26)

0.032

1.11 (1.02–1.22)

0.0230

 Stage III

1.76 (1.51–2.06)

< 0.001

1.63 (1.44–1.84)

< 0.001

1.46 (1.32–1.61)

< 0.001

1.38 (1.26–1.50)

< 0.001

 Stage IV

2.45 (1.98–3.04)

< 0.001

1.99 (1.66–2.39)

< 0.001

1.63 (1.40–1.91)

< 0.001

1.53 (1.31–1.78)

< 0.001

Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us